Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III SOX + sintilimab ± intraperitoneal albumin-bound paclitaxel for HER2-negative gastric/GEJ adenocarcinoma with peritoneal metastasis
ChiCTR2600127138Phase 3Not yet recruiting
- Sponsor
- Sun Yat-sen University Cancer Center
- Start
- Jun 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial of sintilimab in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma and peritoneal carcinomatosis (PC) (2 arms), sponsored by Sun Yat-sen University Cancer Center. Primary endpoint: Overall survival. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
sintilimab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinomaperitoneal carcinomatosis (PC)
Beyond the preview
Go deeper on ChiCTR2600127138.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600127138.